ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients

Chromosomal rearrangements involving the anaplastic lymphoma kinase gene ( ALK ) at 2p23 result in fusion with various partner genes leading to aberrant production of oncogenic protein products in multiple tumor types. Recently, the ALK protein inhibitor crizotinib was shown to be an effective thera...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Modern pathology 2012-11, Vol.25 (11), p.1516-1525
Hauptverfasser:	Sukov, William R, Hodge, Jennelle C, Lohse, Christine M, Akre, Monica K, Leibovich, Bradley C, Thompson, R Houston, Cheville, John C
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/1405 692/699/67/589/1588/1351 692/700/139/422 Adult Aged Aged, 80 and over Anaplastic Lymphoma Kinase Carcinoma, Renal Cell - enzymology Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - surgery Chi-Square Distribution DNA Copy Number Variations Female Gene Amplification Gene Rearrangement Genes Genetic Testing Humans In Situ Hybridization, Fluorescence Kaplan-Meier Estimate Kidney cancer Kidney Neoplasms - enzymology Kidney Neoplasms - genetics Kidney Neoplasms - mortality Kidney Neoplasms - pathology Kidney Neoplasms - surgery Kinases Laboratory Medicine Lymphoma Male Medicine Medicine & Public Health Middle Aged Minnesota Neoplasm Grading Nephrectomy original-article Pathology Patients Phenotype Proportional Hazards Models Proteins Receptor Protein-Tyrosine Kinases - genetics Registries Time Factors Treatment Outcome Tumor Burden Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Chromosomal rearrangements involving the anaplastic lymphoma kinase gene ( ALK ) at 2p23 result in fusion with various partner genes leading to aberrant production of oncogenic protein products in multiple tumor types. Recently, the ALK protein inhibitor crizotinib was shown to be an effective therapy in patients with ALK -rearranged non-small cell lung cancer. The goal of this study was to determine the frequency of ALK alterations in adult renal cell carcinoma (RCC) and define associated clinicopathologic features and outcome. RCCs from a cohort of 534 consecutive surgically treated adult patients were analyzed for alterations of ALK by fluorescence in situ hybridization. ALK rearrangements were identified in 2 of 534 (
ISSN:	0893-3952 1530-0285
DOI:	10.1038/modpathol.2012.107